Written question asked by Baroness Bennett of Manor Castle (Green Party) on Friday, 25 February 2022, in the House of Lords. It was due for an answer on Friday, 11 March 2022. It was answered by Lord Kamall (Conservative) on Monday, 7 March 2022 on behalf of the Department of Health and Social Care.
Abortion: Drugs
- Question
-
To ask Her Majesty's Government what assessment they have made of the impact of ending the home use of mifepristone on (1) waiting times, (2) workforce pressures, and (3) the long-term sustainability, of abortion services.
- Answer
-
Given current pressures on the sector, the Government has provided an extended period for services to plan for the return of face-to-face treatments. We will continue to work with NHS England and NHS Improvement, the Care Quality Commission and abortion providers to ensure a safe and reliable return to face-to-face services.
We are developing a new Sexual and Reproductive Health Strategy which will set out plans to improve reproductive health outcomes and wellbeing. Whilst issues relating to abortion legislation will not be in scope of the Strategy, ensuring the sustainability of accessible and high quality abortion services for women will be a priority.
Secondary information
- Type
- Written question
- Reference
- HL6438
- Session
- 2021-22
- Subjects
- Abortion Drugs Mifepristone
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-03-07 15:59:33 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL6438
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL6438
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2021-22/HL6438